Discrepancy between magnetic resonance and 18F-fluorodeoxyglucose positron emission tomography imaging in a case of borderline ovarian tumor

International Journal of Gynecological Cancer

Volumn 17, Issue 5, 2007, Pages 1031-1033

  Ju, W ^a   Kim, S C ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Borderline ovarian tumor; FDG PET; MR

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

AGED; ANTIGEN DETECTION; ARTICLE; ASCITES TUMOR; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; TUMOR DIAGNOSIS;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34548668436     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00923.x     Document Type: Article

References (15)

1. Trimble CL, Trimble EL. Management of epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1994 55 : S52 61.
2. Kurtz AB, Tsimikas JV, Tempany CM et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis - report of the Radiology Diagnostic Oncology Group. Radiology 1999 212 : 19 27.
3. Rieber A, Nussle K, Stohr I et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. Am J Roentgenol 2001 177 : 123 9.
4. Schröder W, Zimny M, Rudlowski C, Bull U, Rath W. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999 9 : 117 22.
5. Yamashita Y, Torashima M, Hatanaka Y et al. Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging. Radiology 1995 194 : 557 65.
6. Hübner KF, McDonald TW, Niethammer JG et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-18F-deoxyglucose (2-18F-FDG). Gynecol Oncol 1993 51 : 197 204.
7. Karlan BY, Hawkins R, Hoh K et al. Whole-body positron emission tomography with 2-F-18 fluoro2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993 51 : 175 81.
8. Garcia Velloso MJ, Boan Garcia JF, Villar Luque LM, Aramendia Beitia JM, Lopez Garcia G, Richter Echeverria JA. F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence: comparison with CT scan and CA 125. Rev Esp Med Nucl 2003 22 : 217 23.
9. Cho SM, Ha HK, Byun JY et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. Am J Roentgenol 2002 179 : 391 5.
10. Bristow RE, del Carmen MG, Pannu HK et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003 90 : 519 28.
11. Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. PET-CT in recurrent ovarian cancer: initial observations. Radiographics 2004 24 : 209 23.
12. Fenchel S, Grab D, Nuessle K et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002 223 : 780 8.
13. Kurokawa T, Yoshida Y, Kawahara K et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004 109 : 926 32.
14. Kalir T, Wang BY, Goldfischer M et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer 2002 15 : 1078 82.
15. Garzetti GG, Ciavattini A, Goteri G et al. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 1995 56 : 169 74.